Oct 26, 2021 8:35 am EDT iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9
Sep 27, 2021 7:30 am EDT iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
Sep 20, 2021 7:30 am EDT iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
Sep 7, 2021 4:30 pm EDT iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
Aug 25, 2021 7:30 am EDT iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
Jul 15, 2021 5:10 pm EDT iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
Jul 8, 2021 4:15 pm EDT iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
Jun 9, 2021 4:30 pm EDT iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink